Loading clinical trials...
Loading clinical trials...
The purpose of the present study is to evaluate the effect of emotional prosody on the perception of emotional discourse in the schizophrenic spectrum. The investigators hypothesize that participant may use emotional prosody as an emotional cue to understand the emotional content of discourse.
The integration of ortholinguistic and paralinguistic functions in language, particularly of the emotional prosody, is necessary to interact adaptively with others. People in the schizophrenic spectrum have social difficulties. Is emotional prosody comprehension altered in these people? According to Edwards et al. (2002), there is methodological issues concerning the tasks used to answer this question. Investigators built an emotional judgment task more adapted to study the perception of emotional prosody in the schizophrenic spectrum than the classical paradigm designed to evaluate participants with cerebral injury. The investigators have elaborated a material that consists of 140 short sentences (7±2 words) with a simple syntactic structure. The verbal content expressed positive, neutral or negative emotions. These sentences were announced by four professional actors (two female) with an emotional prosody content congruent or inconsistent with the verbal content. Participants will have to evaluate the emotional intensity of the recordings on a five points Likert scale, from strongly negative to strongly positive. Psychotic experiences of all participants will be evaluated too.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
Yes
HDJ François Villon
Cergy-Pontoise, France
Start Date
November 15, 2016
Primary Completion Date
May 27, 2019
Completion Date
May 27, 2019
Last Updated
July 29, 2019
59
ACTUAL participants
Emotional judgment task
BEHAVIORAL
Post-experimental questionnaire
BEHAVIORAL
Recognition task
BEHAVIORAL
Detection task
BEHAVIORAL
CAPE-42
OTHER
Trait Emotional Intelligence Questionnaire
DIAGNOSTIC_TEST
Positive And Negative Syndrome Scale
DIAGNOSTIC_TEST
Mini International Neuropsychiatric Interview
OTHER
Lead Sponsor
Hôpital NOVO
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions